Arca
Skip to content
Tools
Tools

L-arginine

Small molecule in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 2

Approved1

  • Pegzilarginase

Phase 31

  • Pegargiminase

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      PegzilarginaseApprovedImmedica PharmaProtein or peptideHydrolytic enzymeL-arginine hydrolytic enzyme0
      PegargiminasePhase 3Polaris GroupProtein or peptideHydrolytic enzymeL-arginine hydrolytic enzyme6

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 6 in all, from ClinicalTrials.gov.
      A Clinical Study of PA5 in Patients With Advanced Solid TumorsPegargiminasePhase 1RecruitingChongqing Peg-Bio Biopharm Co., Ltd.Jul 14, 2026
      Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)PegargiminasePhase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhDFeb 5, 2026
      Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)PegargiminasePhase 1 / Phase 2RecruitingM.D. Anderson Cancer CenterOct 17, 2023
      Study of ADI-PEG 20 Versus Placebo in Subjects With NASHPegargiminasePhase 2RecruitingPolaris GroupMay 6, 2023
      Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaPegargiminasePhase 3RecruitingPolaris GroupApr 8, 2022
      A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPegargiminasePhase 2 / Phase 3RecruitingGlobal Coalition for Adaptive ResearchMay 31, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4651302, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.